Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients

Annals of Surgery

Volumn 250, Issue 4, 2009, Pages 558-564

  Hunt, Kelly K ^a   Yi, Min ^a   Mittendorf, Elizabeth A ^a   Guerrero, Cynthia ^a   Babiera, Gildy V ^a   Bedrosian, Isabelle ^a   Hwang, Rosa F ^a   Kuerer, Henry M ^a   Ross, Merrick I ^a   Meric Bernstam, Funda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Falsenegative rate; Neoadjuvant chemotherapy; Sentinel lymph node

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AXILLARY LYMPH NODE; BODY MASS; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SENTINEL LYMPH NODE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 70349673336     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b8fd5e     Document Type: Article

References (29)

1. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394-399.
2. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657-3663.
3. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609.
4. Nason KS, Anderson BO, Byrd DR, et al. Increased false-negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89:2187-2194.
5. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539-546.
6. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72-78.
7. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophos-phamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
8. Yared MA, Middleton LP, Smith TL, et al. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol. 2002;26:377-382.
9. Greene FL, Page DL, Fleming ID, et al. Breast Cancer. In: Greene FL, Page DL, Fleming ID, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:223-240.
10. Sanghani M, Balk EM, Cady B. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis. Cancer. 2009;115:1613-1620.
11. Axelsson CK, During M, Christiansen PM, et al. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. Br J Surg. 2009;96:40-46.
12. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-553.
13. Shivers S, Cox C, Leight G, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol. 2002;9:248-255.
14. Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34-40.
15. Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242:593-602.
16. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18: 3480-3486.
17. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23: 2694-2702.
18. Kelly AM, Dwamena B, Cronin P, et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy- systematic review and meta analysis. Acad Radiol. 2009;16:551-563.
19. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 106:4-16.
20. Classe J-M, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French Prospective Multicentric Study. J Clin Oncol. 2008;27:726-732.
21. Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208:333-340.
22. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (>5 cm) invasive breast cancer. Ann Surg Oncol. 2001;8:688-692.
23. Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000;88:2540-2545.
24. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228-233.
25. Beatty JD, Precht LM, Lowe K, et al. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer. Am J Surg. 2009;197: 637-642.
26. Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007;109:1255-1263.
27. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
28. Veronesi U, Galimberti V, Mariani L, et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer. 2005;41:231-237.
29. van der Ploeg IM, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277-1284.